1. Phylogeny  
   CDK9 is a member of the cyclin‐dependent kinase (CDK) family that is evolutionarily conserved among eukaryotes and plays a specialized role in transcription regulation rather than cell cycle progression (asamitsu2022identificationofa pages 1-2). CDK9 is grouped within the CMGC kinase clan, sharing a conserved catalytic domain with other serine/threonine kinases such as CDK7, CDK8, CDK12, and CDK13, and its evolutionary history can be traced back to early eukaryotic ancestors (malumbres2014cyclindependentkinases pages 1-2). Orthologs of CDK9 are present in a wide range of species, with human CDK9 being the functional counterpart of yeast Bur1 kinase, indicating an ancient origin and conservation of the transcription‐regulating function across metazoans (asamitsu2022identificationofa pages 2-4). Phylogenetic analyses, as exemplified in studies on the protein kinase complement of the human genome and subsequent reviews on kinase evolution, place CDK9 in close relation to other transcriptional CDKs that are non–cell cycle‐dependent (malumbres2014cyclindependentkinases pages 3-5).
2. Reaction Catalyzed  
   CDK9 catalyzes the phosphorylation reaction in which ATP and a protein substrate containing serine or threonine residues are converted into ADP and a phosphorylated protein, specifically targeting the C-terminal domain (CTD) of RNA polymerase II in the process (asamitsu2022identificationofa pages 1-2). This reaction is central to the conversion of abortive transcription initiation into productive elongation by transferring a phosphate group from ATP to serine residues within the heptapeptide repeats of the CTD (asamitsu2022identificationofa pages 2-4).
3. Cofactor Requirements  
   The kinase activity of CDK9 is dependent on the binding of ATP as the phosphate donor and requires the presence of divalent cations, predominantly Mg²⁺, to facilitate proper catalytic function (asamitsu2022identificationofa pages 1-2). The catalytic efficiency of CDK9 further relies on its association with regulatory cyclins such as cyclin T1, which act as essential cofactors for its activation (boubacar2024computationalmethodsfor pages 24-27).
4. Substrate Specificity  
   CDK9 exhibits substrate specificity characterized primarily by its activity toward the C-terminal domain of RNA polymerase II, phosphorylating serine residues—especially Ser2—in a context that often shows preferences for adjacent amino acid sequences influenced by local substrate context (johnson2023anatlasof pages 3-4). High-throughput kinase substrate profiling has revealed that CDK9, as a serine/threonine kinase, shows a preference for substrates involved in transcription elongation and factors such as SUPT5H and RDBP, with the consensus sequence reflecting its proline-directed phosphorylation characteristics (johnson2023anatlasof pages 2-3). The substrate motif analysis supports that CDK9, in complex with its cyclin partner, prefers motifs that facilitate the phosphorylation of the RNA polymerase II CTD, aligning with its role in transcription regulation (asamitsu2022identificationofa pages 9-11).
5. Structure  
   CDK9 contains a central catalytic kinase domain that displays the typical bilobal architecture seen in serine/threonine kinases, comprising a smaller N-terminal lobe rich in β-sheets and a larger C-terminal lobe containing predominantly α-helices (malumbres2014cyclindependentkinases pages 6-7). The N-terminal lobe includes the glycine-rich loop (G-loop) involved in ATP binding, while the C-terminal lobe features the activation loop and the C-helix, both of which are critical for substrate recognition and catalytic activity (asamitsu2022identificationofa pages 4-6). Unique structural aspects of CDK9 include a dynamic ATP-binding pocket and a regulatory “hidden cavity” that can be unmasked upon binding of the HIV-1 Tat protein, a feature that has been exploited for inhibitor design (asamitsu2022identificationofa pages 11-13). Additionally, the association with cyclin T1 induces conformational changes that optimally position essential catalytic residues, and the kinase domain possesses key amino acids that are conserved across CDKs, including those in the DFG motif and the catalytic loop (boubacar2024computationalmethodsfor pages 27-33).
6. Regulation  
   CDK9 is regulated at multiple levels through post-translational modifications, protein–protein interactions, and complex formation. Phosphorylation of key residues in the T-loop, such as Thr186, is necessary for full activation of the kinase and is mediated by CDK-activating kinases or via autophosphorylation events that are dependent on cyclin binding (asamitsu2022identificationofa pages 1-2). In addition, CDK9 activity is negatively regulated by its sequestration within the 7SK small nuclear ribonucleoprotein (snRNP) complex, which includes the inhibitory proteins 7SK snRNA and HEXIM1; release from this inhibitory complex is essential for promoting transcription elongation (asamitsu2022identificationofa pages 13-14). The regulatory mechanism is further modulated by interactions with viral proteins such as HIV-1 Tat, which bind to CDK9/cyclin T complexes and induce unique conformational rearrangements that expose otherwise hidden regulatory cavities, thereby altering kinase activity and substrate specificity (asamitsu2022identificationofa pages 6-9).
7. Function  
   CDK9 plays a pivotal role in promoting transcriptional elongation by phosphorylating the C-terminal domain of RNA polymerase II, thereby facilitating the transition from a paused to an elongating form of the polymerase (asamitsu2022identificationofa pages 1-2). Through its activity as a component of the positive transcription elongation factor b (P-TEFb) complex, which forms upon binding with cyclin T1, CDK9 regulates the transcription of genes associated with cell growth, differentiation, and viral pathogenesis (asamitsu2022identificationofa pages 2-4). The kinase also phosphorylates additional substrates such as DSIF, NELF, and transcription factors including MYOD1 and EP300, which in turn contribute to mRNA processing, histone modification, and chromatin remodeling (asamitsu2022identificationofa pages 14-15, candolfi2014roleofcdk9 pages 82-85). CDK9’s role in controlling cytokine-inducible transcription networks further implicates it in the regulation of signaling pathways such as TNF-inducible RELA/p65 and IL-6-inducible STAT3, thereby integrating extracellular signals with transcriptional responses (asamitsu2022identificationofa pages 1-2). Its activity is not only central to normal cellular transcription but also contributes to oncogenic processes and viral replication, particularly in the context of HIV, where CDK9 is hijacked by the HIV Tat protein to promote viral gene expression (asamitsu2022identificationofa pages 11-13, ksionsko2024mechanisticcharacterizationof pages 108-110).
8. Other Comments  
   Several small molecule inhibitors have been developed targeting CDK9, including compounds that bind the ATP-binding site and those that exploit the unique hidden cavity induced by Tat binding; examples include flavopiridol and other novel inhibitors currently under clinical evaluation for cancer and viral infections (asamitsu2022identificationofa pages 6-9, ksionsko2024mechanisticcharacterizationof pages 115-117). CDK9 is also implicated in replication stress responses and genome integrity maintenance, where its kinase activity helps to limit the accumulation of single-stranded DNA under replication arrest conditions (candolfi2014roleofcdk9 pages 17-21). Disease associations for CDK9 prominently include various cancers, especially hematologic malignancies such as T-cell lymphomas, and viral infections where its role in transcription is exploited by pathogens like HIV (ksionsko2024mechanisticcharacterizationof pages 117-120, asamitsu2022identificationofa pages 1-2). In addition, the CDK9/cyclin-K complex can substitute for the canonical CDK9/cyclin-T P-TEFb in vitro, broadening the functional repertoire of CDK9 and its importance in coordinated transcriptional regulation and potentially DNA repair processes (asamitsu2022identificationofa pages 14-15, candolfi2014roleofcdk9 pages 21-28).
9. References  
   asanitsu2022identificationofa pages 1-2; asamitsu2022identificationofa pages 2-4; asamitsu2022identificationofa pages 4-6; asamitsu2022identificationofa pages 6-9; asamitsu2022identificationofa pages 9-11; asamitsu2022identificationofa pages 11-13; asamitsu2022identificationofa pages 13-14; asamitsu2022identificationofa pages 14-15; boubacar2024computationalmethodsfor pages 24-27; boubacar2024computationalmethodsfor pages 27-33; boubacar2024computationalmethodsfor pages 6-7; candolfi2014roleofcdk9 pages 82-85; candolfi2014roleofcdk9 pages 11-17; candolfi2014roleofcdk9 pages 17-21; candolfi2014roleofcdk9 pages 21-28; johnson2023anatlasof pages 1-2; johnson2023anatlasof pages 2-3; johnson2023anatlasof pages 3-4; johnson2023anatlasof pages 10-11; johnson2023anatlasof pages 21-23; ksionsko2024mechanisticcharacterizationof pages 1-5; ksionsko2024mechanisticcharacterizationof pages 103-108; ksionsko2024mechanisticcharacterizationof pages 108-110; ksionsko2024mechanisticcharacterizationof pages 110-113; ksionsko2024mechanisticcharacterizationof pages 115-117; ksionsko2024mechanisticcharacterizationof pages 117-120; ksionsko2024mechanisticcharacterizationof pages 120-122; ksionsko2024mechanisticcharacterizationof pages 122-125; ksionsko2024mechanisticcharacterizationof pages 15-17; ksionsko2024mechanisticcharacterizationof pages 21-23; ksionsko2024mechanisticcharacterizationof pages 52-56; ksionsko2024mechanisticcharacterizationof pages 56-62; ksionsko2024mechanisticcharacterizationof pages 62-67; ksionsko2024mechanisticcharacterizationof pages 88-91; loyer2005roleofcdkcyclin pages 1-2; loyer2005roleofcdkcyclin pages 4-5; loyer2005roleofcdkcyclin pages 7-8; loyer2005roleofcdkcyclin pages 8-9; loyer2005roleofcdkcyclin pages 13-14; malumbres2014cyclindependentkinases pages 1-2; malumbres2014cyclindependentkinases pages 3-5; malumbres2014cyclindependentkinases pages 6-7.

References

1. (asamitsu2022identificationofa pages 1-2): Kaori Asamitsu, Takatsugu Hirokawa, and Takashi Okamoto. Identification of a novel cdk9 inhibitor targeting the intramolecular hidden cavity of cdk9 induced by tat binding. PLOS ONE, 17:e0277024, Nov 2022. URL: https://doi.org/10.1371/journal.pone.0277024, doi:10.1371/journal.pone.0277024. This article has 3 citations and is from a peer-reviewed journal.
2. (asamitsu2022identificationofa pages 13-14): Kaori Asamitsu, Takatsugu Hirokawa, and Takashi Okamoto. Identification of a novel cdk9 inhibitor targeting the intramolecular hidden cavity of cdk9 induced by tat binding. PLOS ONE, 17:e0277024, Nov 2022. URL: https://doi.org/10.1371/journal.pone.0277024, doi:10.1371/journal.pone.0277024. This article has 3 citations and is from a peer-reviewed journal.
3. (asamitsu2022identificationofa pages 14-15): Kaori Asamitsu, Takatsugu Hirokawa, and Takashi Okamoto. Identification of a novel cdk9 inhibitor targeting the intramolecular hidden cavity of cdk9 induced by tat binding. PLOS ONE, 17:e0277024, Nov 2022. URL: https://doi.org/10.1371/journal.pone.0277024, doi:10.1371/journal.pone.0277024. This article has 3 citations and is from a peer-reviewed journal.
4. (asamitsu2022identificationofa pages 2-4): Kaori Asamitsu, Takatsugu Hirokawa, and Takashi Okamoto. Identification of a novel cdk9 inhibitor targeting the intramolecular hidden cavity of cdk9 induced by tat binding. PLOS ONE, 17:e0277024, Nov 2022. URL: https://doi.org/10.1371/journal.pone.0277024, doi:10.1371/journal.pone.0277024. This article has 3 citations and is from a peer-reviewed journal.
5. (asamitsu2022identificationofa pages 4-6): Kaori Asamitsu, Takatsugu Hirokawa, and Takashi Okamoto. Identification of a novel cdk9 inhibitor targeting the intramolecular hidden cavity of cdk9 induced by tat binding. PLOS ONE, 17:e0277024, Nov 2022. URL: https://doi.org/10.1371/journal.pone.0277024, doi:10.1371/journal.pone.0277024. This article has 3 citations and is from a peer-reviewed journal.
6. (asamitsu2022identificationofa pages 9-11): Kaori Asamitsu, Takatsugu Hirokawa, and Takashi Okamoto. Identification of a novel cdk9 inhibitor targeting the intramolecular hidden cavity of cdk9 induced by tat binding. PLOS ONE, 17:e0277024, Nov 2022. URL: https://doi.org/10.1371/journal.pone.0277024, doi:10.1371/journal.pone.0277024. This article has 3 citations and is from a peer-reviewed journal.
7. (boubacar2024computationalmethodsfor pages 24-27): R Djibo Boubacar. Computational methods for drug repurposing and applications. Unknown journal, 2024.
8. (boubacar2024computationalmethodsfor pages 27-33): R Djibo Boubacar. Computational methods for drug repurposing and applications. Unknown journal, 2024.
9. (candolfi2014roleofcdk9 pages 82-85): N Candolfi. Role of cdk9 in skeletal muscle. Unknown journal, 2014.
10. (johnson2023anatlasof pages 3-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
11. (ksionsko2024mechanisticcharacterizationof pages 1-5): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
12. (ksionsko2024mechanisticcharacterizationof pages 110-113): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
13. (ksionsko2024mechanisticcharacterizationof pages 120-122): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
14. (ksionsko2024mechanisticcharacterizationof pages 122-125): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
15. (ksionsko2024mechanisticcharacterizationof pages 21-23): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
16. (ksionsko2024mechanisticcharacterizationof pages 52-56): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
17. (loyer2005roleofcdkcyclin pages 13-14): P LOYER, J TREMBLEY, R KATONA, V KIDD, and J LAHTI. Role of cdk/cyclin complexes in transcription and rna splicing. Cellular Signalling, 17:1033-1051, Sep 2005. URL: https://doi.org/10.1016/j.cellsig.2005.02.005, doi:10.1016/j.cellsig.2005.02.005. This article has 236 citations and is from a peer-reviewed journal.
18. (malumbres2014cyclindependentkinases pages 1-2): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
19. (malumbres2014cyclindependentkinases pages 3-5): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
20. (malumbres2014cyclindependentkinases pages 6-7): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
21. (asamitsu2022identificationofa pages 11-13): Kaori Asamitsu, Takatsugu Hirokawa, and Takashi Okamoto. Identification of a novel cdk9 inhibitor targeting the intramolecular hidden cavity of cdk9 induced by tat binding. PLOS ONE, 17:e0277024, Nov 2022. URL: https://doi.org/10.1371/journal.pone.0277024, doi:10.1371/journal.pone.0277024. This article has 3 citations and is from a peer-reviewed journal.
22. (asamitsu2022identificationofa pages 6-9): Kaori Asamitsu, Takatsugu Hirokawa, and Takashi Okamoto. Identification of a novel cdk9 inhibitor targeting the intramolecular hidden cavity of cdk9 induced by tat binding. PLOS ONE, 17:e0277024, Nov 2022. URL: https://doi.org/10.1371/journal.pone.0277024, doi:10.1371/journal.pone.0277024. This article has 3 citations and is from a peer-reviewed journal.
23. (boubacar2024computationalmethodsfor pages 6-7): R Djibo Boubacar. Computational methods for drug repurposing and applications. Unknown journal, 2024.
24. (candolfi2014roleofcdk9 pages 11-17): N Candolfi. Role of cdk9 in skeletal muscle. Unknown journal, 2014.
25. (candolfi2014roleofcdk9 pages 17-21): N Candolfi. Role of cdk9 in skeletal muscle. Unknown journal, 2014.
26. (candolfi2014roleofcdk9 pages 21-28): N Candolfi. Role of cdk9 in skeletal muscle. Unknown journal, 2014.
27. (johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
28. (johnson2023anatlasof pages 10-11): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
29. (johnson2023anatlasof pages 2-3): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
30. (johnson2023anatlasof pages 21-23): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
31. (ksionsko2024mechanisticcharacterizationof pages 103-108): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
32. (ksionsko2024mechanisticcharacterizationof pages 108-110): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
33. (ksionsko2024mechanisticcharacterizationof pages 115-117): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
34. (ksionsko2024mechanisticcharacterizationof pages 117-120): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
35. (ksionsko2024mechanisticcharacterizationof pages 15-17): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
36. (ksionsko2024mechanisticcharacterizationof pages 56-62): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
37. (ksionsko2024mechanisticcharacterizationof pages 62-67): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
38. (ksionsko2024mechanisticcharacterizationof pages 88-91): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
39. (loyer2005roleofcdkcyclin pages 1-2): P LOYER, J TREMBLEY, R KATONA, V KIDD, and J LAHTI. Role of cdk/cyclin complexes in transcription and rna splicing. Cellular Signalling, 17:1033-1051, Sep 2005. URL: https://doi.org/10.1016/j.cellsig.2005.02.005, doi:10.1016/j.cellsig.2005.02.005. This article has 236 citations and is from a peer-reviewed journal.
40. (loyer2005roleofcdkcyclin pages 4-5): P LOYER, J TREMBLEY, R KATONA, V KIDD, and J LAHTI. Role of cdk/cyclin complexes in transcription and rna splicing. Cellular Signalling, 17:1033-1051, Sep 2005. URL: https://doi.org/10.1016/j.cellsig.2005.02.005, doi:10.1016/j.cellsig.2005.02.005. This article has 236 citations and is from a peer-reviewed journal.
41. (loyer2005roleofcdkcyclin pages 7-8): P LOYER, J TREMBLEY, R KATONA, V KIDD, and J LAHTI. Role of cdk/cyclin complexes in transcription and rna splicing. Cellular Signalling, 17:1033-1051, Sep 2005. URL: https://doi.org/10.1016/j.cellsig.2005.02.005, doi:10.1016/j.cellsig.2005.02.005. This article has 236 citations and is from a peer-reviewed journal.
42. (loyer2005roleofcdkcyclin pages 8-9): P LOYER, J TREMBLEY, R KATONA, V KIDD, and J LAHTI. Role of cdk/cyclin complexes in transcription and rna splicing. Cellular Signalling, 17:1033-1051, Sep 2005. URL: https://doi.org/10.1016/j.cellsig.2005.02.005, doi:10.1016/j.cellsig.2005.02.005. This article has 236 citations and is from a peer-reviewed journal.